Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer

Digestion ◽  
2018 ◽  
Vol 99 (1) ◽  
pp. 79-85 ◽  
Author(s):  
Yuji Miyamoto ◽  
Yukiharu Hiyoshi ◽  
Takahiko Akiyama ◽  
Yuki Kiyozumi ◽  
Kojiro Eto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Skeletal Muscle ◽  
Prognostic Factor ◽  
Metastatic Colorectal Cancer ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Poor Prognostic Factor ◽  
Line Chemotherapy

scholarly journals No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Sami Antoun ◽  
Mohamed Amine Bayar ◽  
Valérie Dyevre ◽  
Emilie Lanoy ◽  
Cristina Smolenschi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Skeletal Muscle ◽  
Metastatic Colorectal Cancer ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
First Line ◽  
Line Chemotherapy

scholarly journals Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients

2018 ◽  
Vol 9 (5) ◽  
pp. 909-919 ◽  
Author(s):  
Sophie A. Kurk ◽  
Petra H.M. Peeters ◽  
Bram Dorresteijn ◽  
Pim A. de Jong ◽  
Marion Jourdan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Skeletal Muscle ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Systemic Treatments ◽  
Colorectal Cancer Patients

scholarly journals Associations of pre-existing co-morbidities with skeletal muscle mass and radiodensity in patients with non-metastatic colorectal cancer

2018 ◽  
Vol 9 (4) ◽  
pp. 654-663 ◽  
Author(s):  
Jingjie Xiao ◽  
Bette J. Caan ◽  
Erin Weltzien ◽  
Elizabeth M. Cespedes Feliciano ◽  
Candyce H. Kroenke ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Skeletal Muscle ◽  
Metastatic Colorectal Cancer ◽  
Muscle Mass ◽  
Skeletal Muscle Mass

scholarly journals Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients

2019 ◽  
Vol 10 (4) ◽  
pp. 803-813 ◽  
Author(s):  
Sophie Kurk ◽  
Petra Peeters ◽  
Rebecca Stellato ◽  
B. Dorresteijn ◽  
Pim Jong ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Skeletal Muscle ◽  
Mass Loss ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Muscle Mass Loss ◽  
Colorectal Cancer Patients

scholarly journals Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Song Ee Park ◽  
Jin Hwa Choi ◽  
Jae Yong Park ◽  
Beom Jin Kim ◽  
Jae Gyu Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Skeletal Muscle ◽  
Body Weight ◽  
Prognostic Factor ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Palliative Chemotherapy ◽  
Chemotherapy Response ◽  
First Line ◽  
Poor Prognostic Factor

Abstract Cancer causes muscle mass loss, which is associated with a poor prognosis. Chemotherapy may also reduce muscle mass. We investigated skeletal muscle mass change during palliative chemotherapy for advanced gastric cancer (AGC) and its association with treatment outcomes. We retrospectively reviewed 111 consecutive AGC patients who underwent first-line palliative chemotherapy. Skeletal muscle area was measured before and after chemotherapy at the third lumbar vertebra level using computed tomography scans. We compared skeletal muscle index (SMI), body mass index (BMI), and body weight changes to chemotherapy response and survival. The 80 male and 31 female patients’ median age was 65 (range 31–87) years, and 46.8% had sarcopenia at baseline. Median pre-chemotherapy to post-chemotherapy SMI, BMI, and body weight decreases were − 4.5 cm2/m2 (− 11.3%) (P < 0.001); − 0.7 kg/m2 (− 3.2%) (P < 0.001); and − 2.0 kg (− 3.5%) (P < 0.001), respectively. Median SMI decreases for patients with objective response, stable disease, and disease progression were − 4.0 cm2/m2 (range − 20.1 ~ 9.5); − 4.5 cm2/m2 (range − 19.8 ~ 0.8); and − 3.8 cm2/m2 (range: − 17.6 ~ 0.1), respectively. Response to chemotherapy was not associated with SMI decrease (P = 0.463). In multivariable analysis, sarcopenia at baseline (HR 1.681; 95% CI 1.083–2.609, P = 0.021), decreased SMI (HR 1.620; 95% CI 1.041–2.520; P = 0.032) were significant poor prognostic factors for survival. Skeletal muscle mass decreased significantly during chemotherapy in AGC patients, but was not associated with chemotherapy response. Decreased SMI was a poor prognostic factor in AGC patients during first-line palliative chemotherapy.

scholarly journals Loss of skeletal muscle mass after curative gastrectomy is a poor prognostic factor

2018 ◽  
Author(s):  
Naruji Kugimiya ◽  
Eijiro Harada ◽  
Kazuhito Oka ◽  
Daichi Kawamura ◽  
Yuki Suehiro ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Prognostic Factor ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Curative Gastrectomy ◽  
Poor Prognostic Factor
Sign in / Sign up

Export Citation Format

Share Document